Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Dec 27:7:223.
doi: 10.1186/1748-717X-7-223.

Preclinical models in radiation oncology

Jenna Kahn  1 , Philip J Tofilon, Kevin Camphausen
Affiliations
Review

Preclinical models in radiation oncology

Jenna Kahn et al. Radiat Oncol. .

Abstract

As the incidence of cancer continues to rise, the use of radiotherapy has emerged as a leading treatment modality. Preclinical models in radiation oncology are essential tools for cancer research and therapeutics. Various model systems have been used to test radiation therapy, including in vitro cell culture assays as well as in vivo ectopic and orthotopic xenograft models. This review aims to describe such models, their advantages and disadvantages, particularly as they have been employed in the discovery of molecular targets for tumor radiosensitization. Ultimately, any model system must be judged by its utility in developing more effective cancer therapies, which is in turn dependent on its ability to simulate the biology of tumors as they exist in situ. Although every model has its limitations, each has played a significant role in preclinical testing. Continued advances in preclinical models will allow for the identification and application of targets for radiation in the clinic.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Limitations and advantages of preclinical model systems in radiation oncology.
See this image and copyright information in PMC

References

    1. SEER. Surveillance epidemiology and End results (SEER), national cancer institiute. http://www.cancergov.com.
    1. Tofilon PJ, Camphausen K. Molecular targets for tumor radiosensitization. Chem Rev. 2009;109(7):2974–2988. doi: 10.1021/cr800504x. - DOI - PMC - PubMed
    1. Hall EJ. Radiobiology for the radiologist. 7th. Philadelphia: Lippincott Williams and Wilkins; 2011.
    1. Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer J Int du cancer. 2005;114(3):380–386. doi: 10.1002/ijc.20774. - DOI - PubMed
    1. Mehrian Shai R, Reichardt JK, Ya-Hsuan H, Kremen TJ, Liau LM, Cloughesy TF, Mischel PS, Nelson S, Mehrian Shai R, Reichardt JK, Ya-Hsuan H, Kremen TJ, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Brain Res Mol Brain Res. 2005;136(1-2):99–103. doi: 10.1016/j.molbrainres.2005.01.017. - DOI - PubMed

Substances

LinkOut - more resources